Related Experiment Video
Updated: Jul 31, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Novel therapeutic strategies in prostate cancer
Avi S Retter1, James L Gulley, William L Dahut
1Genitourinary Branch, Medical Oncology Clinical Research Unit, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. rettera@mail.nih.gov
Abstract:
Prostate cancer is the most common noncutaneous cancer in American men and the second most common cause of death. It is estimated that in 2003, 220,900 new cases will be diagnosed and 28,900 men will die from the disease.1 Hormonal therapy via surgical or chemical castration is the mainstay of treatment for metastatic prostate cancer. While this is quite effective initially, with time patients become refractory to this treatment and may require additional therapy. There have been a substantial number of novel agents that have been developed in the last 10 years that show promise in the treatment of patients with prostate cancer, when used alone or when combined with current approaches (Table 1).
Insights
Prostate cancer is a leading cause of cancer death in men. Novel agents are showing promise for treating metastatic prostate cancer when current hormonal therapies become ineffective.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is the most common noncutaneous cancer in American men.
- It is the second leading cause of cancer death in men.
- Metastatic prostate cancer is primarily treated with hormonal therapy.
Purpose of the Study:
- To review novel agents for prostate cancer treatment.
- To discuss the role of these agents in overcoming hormonal therapy resistance.
Main Methods:
- Literature review of novel therapeutic agents for prostate cancer.
- Analysis of treatment approaches for metastatic prostate cancer.
Main Results:
- Hormonal therapy is initially effective but often leads to resistance.
- Numerous novel agents have been developed in the last decade.
- These agents show promise when used alone or in combination with existing treatments.
Conclusions:
- There is a need for new therapeutic strategies for advanced prostate cancer.
- Novel agents offer potential new treatment options for patients refractory to hormonal therapy.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...